[Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV]

J L Misset; P Pouillart; J L Amiel; L Schwarzenberg; M Hayat; F de Vassal; M Musset; D Belpomme; C Jasmin; C Albahary; R Depierre; G Mathé

[Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV]

Nouv Presse Med. 1975 Dec 20;4(44):3117-20.

[Article in French]

Authors

J L Misset, P Pouillart, J L Amiel, L Schwarzenberg, M Hayat, F de Vassal, M Musset, D Belpomme, C Jasmin, C Albahary, R Depierre, G Mathé

PMID: 768904

Abstract

This work presents the results obtained on 24 patients with disseminated lymphosarcoma and reticulosarcoma (stage III and IV) with a cyclic combination chemotherapy which combines adriamycin, epipodophyllotoxin (VM 26), cyclophosphamide and prednisone. The complete remission rate is 58 p.cent of the patients who entered the trial, the response rate is 75 p.cent. Tolerance of the regimen is good in general from the hematological point of view.

Publication types

English Abstract

MeSH terms

Adolescent
Adult
Aged
Child
Cyclophosphamide / therapeutic use*
Doxorubicin / therapeutic use*
Drug Therapy, Combination
Drug Tolerance
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Non-Hodgkin / drug therapy*
Male
Middle Aged
Neoplasm Seeding
Podophyllotoxin / analogs & derivatives*
Prednisone / therapeutic use*
Remission, Spontaneous
Teniposide / therapeutic use*

Substances

Doxorubicin
Cyclophosphamide
Teniposide
Podophyllotoxin
Prednisone